Vasopressin Global Market Report 2026

Vasopressin, commonly referred to as antidiuretic hormone (ADH), is a peptide hormone synthesized by the hypothalamus and secreted by the posterior pituitary gland into the bloodstream. It has a vital function in controlling the body's water levels and blood pressure, sustaining water balance, regulating blood pressure, and managing responses to stress.

Vasopressin is primarily available in the forms of intravenous injection, intramuscular injection, and subcutaneous injection. When administered through intravenous injection, the hormone is delivered directly into the bloodstream. These injections are utilized for various conditions, including anti-diuretic hormone deficiency, vasodilatory shock, gastrointestinal bleeding, ventricular tachycardia, and fibrillation, and are employed by different end-users such as hospitals, clinics, and others.

Tariffs have affected the vasopressin market by increasing the cost of peptide synthesis inputs, sterile injectable manufacturing materials, and specialized pharmaceutical packaging components. These impacts are most pronounced in intravenous vasopressin formulations, particularly in regions that rely heavily on imported inputs. Rising tariff related expenses have contributed to higher treatment costs in hospital and critical care settings. This has influenced procurement planning and inventory management for emergency and intensive care medicines. However, tariffs are also supporting localized manufacturing of injectable hormone therapies and encouraging greater regional supply chain self sufficiency over the long term.

The vasopressin market research report is one of a series of new reports from The Business Research Company that provides vasopressin market statistics, including vasopressin industry global market size, regional shares, competitors with a vasopressin market share, detailed vasopressin market segments, market trends and opportunities, and any further data you may need to thrive in the vasopressin industry. This vasopressin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vasopressin market size has grown rapidly in recent years. It will grow from $1.57 billion in 2025 to $1.79 billion in 2026 at a compound annual growth rate (CAGR) of 14.0%. The growth in the historic period can be attributed to established role in antidiuretic hormone deficiency, widespread use in gastrointestinal bleeding, growth of intensive care units, proven efficacy in shock management, expansion of hospital emergency services.

The vasopressin market size is expected to see rapid growth in the next few years. It will grow to $2.88 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing incidence of septic shock, rising ICU admissions, advancements in critical care protocols, growing awareness of hormonal disorders, expansion of emergency medicine infrastructure. Major trends in the forecast period include rising use in critical care and shock management, growing demand in sepsis and intensive care units, increased adoption in hormonal deficiency treatment, expansion of injectable hormone therapies, higher focus on emergency care applications.

The increasing prevalence of diabetes is expected to drive the growth of the vasopressin market in the coming years. Diabetes is a chronic health condition marked by elevated blood glucose levels due to the body's inability to produce or effectively use insulin. The rise in diabetes prevalence is linked to factors such as increasing obesity rates, stress and mental health issues, and genetic predisposition. Vasopressin plays a key role in managing central diabetes insipidus by helping to maintain normal water balance and alleviating symptoms like excessive urination and thirst. For example, in June 2024, according to the National Health Service (NHS), a UK-based government department, the number of individuals under 40 with diabetes increased from 173,166 in 2022 to 216,440 in 2023. This considerable growth underscores a concerning trend among younger populations. As a result, the rising prevalence of diabetes is contributing to the expansion of the vasopressin market.

The increasing geriatric population is expected to drive the growth of the vasopressin market in the coming years. The geriatric population refers to older adults, generally aged 65 years and above, who often need specialized healthcare and support due to age-related physiological changes. The growth of this population is mainly attributed to rising life expectancy, which enables people to live longer, and declining birth rates, which reduce the proportion of younger individuals in the population. Vasopressin benefits the geriatric population by helping maintain blood pressure stability and enhancing kidney function, thereby addressing age-related cardiovascular and renal vulnerabilities. For example, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration reported that in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This figure is projected to increase to 22.1 million by 2072, accounting for 27% of the population. Hence, the growing geriatric population is contributing to the expansion of the vasopressin market.

Major companies in the vasopressin market are focusing on developing innovative solutions such as higher-concentration ready-to-use vasopressin formulations to enhance dosing accuracy, shorten preparation time, and improve safety in critical-care environments. Higher-concentration ready-to-use vasopressin is a premixed intravenous formulation with a higher unit-per-mL ratio that removes the need for bedside dilution, allows faster initiation, and reduces dosing errors during the treatment of vasodilatory shock. For example, in March 2024, Baxter Healthcare Corporation, a US-based pharmaceutical and medical device company, received FDA approval for Vasopressin in 0.9% Sodium Chloride Injection, 50 units/50 mL (1 unit/mL), a concentrated ready-to-use vasopressin formulation with a fixed 1-unit/mL strength that minimizes frequent bag changes, a premixed single-dose format that eliminates compounding steps, and compatibility with standard infusion systems to simplify administration in emergency and intensive-care settings.

Major companies operating in the vasopressin market are Pfizer Inc., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Ferring Pharmaceuticals, Amphastar Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals Inc., Eagle Pharmaceuticals Inc., Par Pharmaceutical Holdings Inc., Fresenius Kabi, Nordic Pharma Inc., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Inc., Amneal Pharmaceuticals Inc., Bachem Holding AG, BCN Peptides SA, Laboratorio ELEA S.A.C.I.F. y A., Hainan Zhonghe Pharmaceutical Co. Ltd., Cumberland Pharmaceuticals Inc., AMOMED Pharma GmbH

North America was the largest region in the vasopressin market in 2025. The regions covered in the vasopressin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the vasopressin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vasopressin market consists of sales of arginine vasopressin (AVP), vasopressin receptor, oral tablets, sublingual tablets, nasal sprays, and oil-repository material. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vasopressin Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses vasopressin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vasopressin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The vasopressin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Intravenous Injection; Intramuscular Injection; Subcutaneous Injection
• 2) By Application: Anti-Diuretic Hormone Deficiency; Vasodilatory Shock; Gastrointestinal Bleeding; Ventricular Tachycardia And Fibrillation
• 3) By End-User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Intravenous Injection: Standard Iv Vasopressin Injection; High-Dose Iv Vasopressin Injection; Iv Vasopressin For Sepsis And Shock Treatment; Iv Vasopressin For Post-Operative Care
• 2) By Intramuscular Injection: Standard Im Vasopressin Injection; Intramuscular Vasopressin For Hormonal Imbalance; Vasopressin Injection For Acute Hemorrhage Control
• 3) By Subcutaneous Injection: Subcutaneous Vasopressin For Diabetes Insipidus
• Companies Mentioned: Pfizer Inc.; Baxter International Inc.; Otsuka Pharmaceutical Co. Ltd.; Ferring Pharmaceuticals; Amphastar Pharmaceuticals Inc.; Mallinckrodt Pharmaceuticals Inc.; Eagle Pharmaceuticals Inc.; Par Pharmaceutical Holdings Inc.; Fresenius Kabi; Nordic Pharma Inc.; Aurobindo Pharma Limited; Dr. Reddy's Laboratories Ltd.; Apotex Inc.; Amneal Pharmaceuticals Inc.; Bachem Holding AG; BCN Peptides SA; Laboratorio ELEA S.A.C.I.F. y A.; Hainan Zhonghe Pharmaceutical Co. Ltd.; Cumberland Pharmaceuticals Inc.; AMOMED Pharma GmbH
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.